Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo

International Journal of Cancer

Volumn 121, Issue 6, 2007, Pages 1197-1204

  Gonzalez Moreno, Oscar ^a,b   Segura, Victor ^b   Serrano, Diego ^a,b   Nguewa, Paul ^a   De Las Rivas, Javier ^c   Calvo, Alfonso ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CSIC   (Spain)

Author keywords

AKT; Chemotherapy; Gene expression; MAPK; Microarrays; Prostate carcinoma

Indexed keywords

CASPASE 3; DOCETAXEL; ETOPOSIDE; METHYLSELENINIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; PROTEIN KINASE B; SELENIUM DERIVATIVE; SODIUM SELENITE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETOPOSIDE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOSELENIUM COMPOUNDS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548068305     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22764     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Diaz M, Patterson SG. Management of androgen-independent prostate cancer. Cancer Control 2004;11:364-73.
3. Bostwick DG. Prostatic intraepithelial neoplasia. Curr Urol Rep 2000;1:65-70.
4. Nelson MA, Porterfield BW, Jacobs ET, Clark LC. Se and prostate cancer prevention. Semin Urol Oncol 1999;17:91-6.
5. Dong Y, Ganther HE, Stewart C, Ip C. Identification of molecular targets associated with Se-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 2002;62:708-14.
6. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for Se-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003;63:52-9.
7. Zu K, Ip C. Synergy between Se and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003;63:6988-95.
8. Cho SD, Jiang C, Malewicz B, Dong Y, Young CY, Kang KS, Lee YS, Ip C, Lu J. Methyl Se metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 2004;3:605-11.
9. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994;91:11236-40.
10. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002;62:5325-35.
11. Jorcyk CL, Liu ML, Shibata MA, Maroulakou IG, Komschlies KL, McPhaul MJ, Resau JH, Green JE. Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. Prostate 1998;34:10-22.
12. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
13. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
14. Martinez-Cruz LA, Rubio A, Martinez-Chantar ML, Labarga A, Barrio I, Podhorski A, Segura V, Sevilla Campo JL, Avila MA, Mato JM. GARBAN: genomic analysis and rapid biological annotation of cDNA microarray and proteomic data. Bioinformatics 2003;19:2158-60.
15. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20:1453-4.
16. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 2004;299:286-93.
17. Abasolo I, Montuenga LM, Calvo A. Adrenomedullin prevents apoptosis in prostate cancer cells. Regul Pept 2006;133:115-22.
18. Husbeck B, Bhattacharyya RS, Feldman D, Knox SJ. Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther 2006;5:2078-2085.
19. Vanveldhuizen PJ, Zulfiqar M, Banerjee S, Cherian R, Saxena NK, Rabe A, Thrasher JB, Banerjee SK. Differential expression of NP-1 in malignant and benign prostatic stromal tissue. Oncol Rep 2003;10:1067-71.
20. Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett 2006;231:1-11.
21. Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P, Bouchier-Hayes DJ, Harmey JH. A peptide corresponding to the NP-1-binding site on VEGF(165) induces apoptosis of NP-1-expressing breast tumour cells. Br J Cancer 2005;92:328-33.
22. McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer, Drugs 2005;65:2287-94; discussion 2295-7
23. Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 2003;98:269-76.
24. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated Se metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-6.
25. Soares CR, Shibata MA, Green JE, Jorcyk CL. Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression. Neoplasia 2002;4:112-20.
26. Hu H, Jiang C, Li G, Lu J. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 2005;26:1374-81.
27. Jiang C, Ganther H, Lu J. Monomethyl Se-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 2000;29:236-50.
28. Shankar DB, Sakamoto KM. The role of cyclic-AMP binding protein (CREB) in leukemia cell proliferation and acute leukemias. Leuk Lymphoma 2004;45:265-70.
29. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004;64:7156-68.